Navigation Links
AviaraDx Presents at 2007 BIOCOM Investor Conference
Date:10/5/2007

Newly formed molecular diagnostic company launches two oncology tests

SAN DIEGO, Oct. 5 /PRNewswire/ -- AviaraDx, Inc., announced today that the company is scheduled to provide a corporate overview of its molecular diagnostic test offerings and development programs at the 2007 BIOCOM Investor Conference. The presentation is scheduled for Thursday, November 1st, at 2:30 p.m. in the Rancho Santa Fe ballroom of the San Diego Marriott Del Mar Hotel, 11966 El Camino Real, San Diego, CA 92130.

About AviaraDx, Inc.

AviaraDx discovers, develops, and commercializes new molecular diagnostic tests in oncology, enabling physicians to personalize cancer treatment through better understanding of the molecular biology underlying a patient's tumor. Our tests improve the classification of cancer, support physicians to provide their patients with a more specific prognosis or individual risk assessment, and will provide information critical to predict treatment response to a given therapeutic regimen. AviaraDx offers diagnostic tests to qualified physicians or laboratories through its CAP-certified CLIA laboratory service operations. The company's first diagnostic test offerings are based on its proprietary technologies for the molecular classification of metastatic cancer, CancerTYPE ID(TM), and its H/I(TM) (HOXB13/IL17BR) test to assess risk of recurrence and response to endocrine therapy in certain breast cancer patients.

CONTACT:

Antonius Schuh, Ph.D.

Chief Executive Officer

+1 (760) 579 0500

aschuh@aviaradx.com


'/>"/>
SOURCE AviaraDx, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related medicine news :

1. Ovarian Cancer Presents ‘Target Symptoms’ Six Months Before Diagnosi
2. IDM Pharma Presents Preliminary Results of Melanoma Vaccine Clinical Trial
3. Living Liver Donor Who Saved Life of Mother-in-law Represents Cedars-Sinai in Rose Parade
4. Childrens Hospital Boston Presents at the Society for Adolescent Medicine Annual Meeting
5. Monogram Presents Results of First ETag Breast Cancer Studies
6. Novagali Pharma Presents Phase III Clinical Trial of Vekacia(R) for Vernal Keratoconjunctivitis
7. Abbott Laboratories to buy Biocompatibles cardiovascular stent business
8. International Conference On Malaria - Laveran To Genomics
9. African Conference to Combat AIDS
10. International conference on Ayurveda to be held on Kerala
11. 5th European Breast Cancer Conference Talks about Everything from Patient to Oncologist

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/29/2009)...9 The following is an investment o...search, Inc. ,, Intellivest Securities Research...visor, has published a Report on BioClinica, Inc. ...al, biotechnology and medical device industries. ... process and submit medical imaging portions of th...
(Date:11/29/2009)...ections begin to form between brain cells almost i...to a study published this week in Nature . Led by...a Cruz, the study involved detailed observations o...ain during motor learning. , The researchers stu...slot to get a seed. They observed rapid growth of ...
(Date:11/29/2009)...nd of treatment equals a $41,000 pay raise, resear...ay News) -- Psychological therapy may be much more...aise or winning a lottery prize, suggests an Engli...nds of people who provided information about their...happiness from a $1,329 course of therapy was so s...
(Date:11/29/2009)...aditional healthcare,s uncertain future and rising...tive care. Affordable Acupuncture Scottsdale answe...vember 29, 2009 -- Affordable Acupuncture, LLC ope...has been met with enthusiasm and gratitude. Its in...buted to two things, need and cost. "As far ...
(Date:11/28/2009)...ikely to consider change after 30-minute psychosoc..., Nov. 27 (HealthDay News) -- A program that gets ...ld stop their dangerous behavior may lead to signi...found. , The new study included 184 men and wom...ions, who were randomly assigned to one of two int...
Breaking Medicine News(10 mins):Health News:Research Report on BioClinica, Inc. as Speculative Buy 2Health News:Study shows new brain connections form rapidly during motor learning 2Health News:Study shows new brain connections form rapidly during motor learning 3Health News:Psychotherapy Can Boost Happiness More Than Money: Study 2Health News:Affordable Acupuncture Greeted with Open Arms by Scottsdale and Phoenix Communities 2Health News:Drunk Drivers May Respond to Brief Motivational Interview 2
...ov. 8 The Connecticut,Trial Lawyers Association (...aling that, for several years Connecticut Medical ... excessive premiums causing their overhead,to soar...nt actuarial firm, is based on the most recent fin...
...Nov. 8 University,HealthSystem Consortium (UHC), ...pitals and health systems, has signed a new five-y...; TSX: TOC) for its comparative,database and bench...evaluate their,performance, compare it to other or...
...enry Ford Hospital is hosting a,day-long program f...provide,up-to-date information on stroke preventio... quality of life. The program, sponsored by the d... Henry Ford Hospital has been designated a Stroke,...
...procedure from Colorado-based company, DENVER, No...s patent-pending Regenexx(TM) procedure, which use...d cartilage -- a welcome relief for the,more than ...vailable today," said Chris Centeno, M.D., creator...
...Y, November 8, 2007- Telemedicine and e-Health, a ... Ann Liebert Inc., publishers ( www.liebertpub.com...eginning in 2008; a new section, MEDICAL CONNECTIV...sions, case studies, interviews with leaders in th...
... the worlds largest molecular imaging and nuclear ...ar $24,000 fellowship program in the United States...eir career. , The SNM Wagner-Torizuka Fellowship...ant contributions to the field of molecular imagin...
Other Medicine News:Health News:Connecticut Trial Lawyers Ask Doctors to Question Insurer's Excess Profits 2Health News:Contract Renewal Extends Thomson Healthcare's Long-Standing Relationship with University Hospitals 2Health News:New Non-Surgical Stem-Cell Procedure Relieves Degenerative Joint Disease 2Health News:Telemedicine publication expands coverage 2Health News:SNM/Nihon Medi-Physics sponsor new fellowship program for Japanese physicians 2
(Date:11/25/2009)... , , PHILADELPHIA, Nov. 25 /PRNewswi...oday that Dr. Michael J. McKelvey, the Company,s P... Executive Vice President and CFO, are scheduled t...Care Conference at 1:30 PM EST on December 1, 2009...ies may access the presentation by visiting the Co...
(Date:11/25/2009)... , , BRIDGEWATER, N.J., Nov. 25 /PRNewswir...ELENCE® (etravirine) tablets, a non-nucleosid...CE is the only NNRTI specifically indicated for us...cing virologic failure with HIV-1 strains resistan...s. The traditional approval is based on 48-week d...
(Date:11/25/2009)... , , RANCHO CORDOVA, Calif., Nov. 25 /PRN...idiary of American Pacific Corporation (Nasdaq: A...mental Responsibility and Sustainability Award at ...ed by the California Manufacturers and Technology ...ssociation (IEA) and the Chemical Industry Council...
Breaking Medicine Technology:ERT to Present at the 21st Annual Piper Jaffray Health Care Conference on December 1, 2009 2U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 2U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 3U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 4U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 5AMPAC Fine Chemicals Receives Prestigious Award at California's Annual Statewide Environmental Summit 2AMPAC Fine Chemicals Receives Prestigious Award at California's Annual Statewide Environmental Summit 3Michigan Life Science and Innovation Center Opens in Former Pfizer Facility 5064 1Michigan Life Science and Innovation Center Opens in Former Pfizer Facility 5064 2Michigan Life Science and Innovation Center Opens in Former Pfizer Facility 5064 3Results from Abbotts PROSPECT Study Provide New Insight into Role of Vulnerable Plaque in Coronary Artery Disease 5062 1Results from Abbotts PROSPECT Study Provide New Insight into Role of Vulnerable Plaque in Coronary Artery Disease 5062 2Results from Abbotts PROSPECT Study Provide New Insight into Role of Vulnerable Plaque in Coronary Artery Disease 5062 3Results from Abbotts PROSPECT Study Provide New Insight into Role of Vulnerable Plaque in Coronary Artery Disease 5062 4Environmental Chemicals May Affect Male Reproduction 58306 1Environmental Chemicals May Affect Male Reproduction 58306 2
...K, Calif.--(BUSINESS WIRE)--Jun,4, 2007 - ChemGene...ed today the presentation of data from its Quiname...scalation study,designed to identify a genotypica...ted patients with a variety of solid tumors. The,k... that dose level,could be optimised according to p...
... of progression-free survival,in the SPARC Phase 3...ative risk of disease progression for patients rec...Taxotere use,geographies, as well as presence or ...ssion in the SPARC trial - radiologic,progression ... 36%,reduction in relative risk of disease progres...
Other Medicine Technology:ChemGenex Reports Successful Personalized Dosing of Quinamed at,ASCO 2ChemGenex Reports Successful Personalized Dosing of Quinamed at,ASCO 3ChemGenex Reports Successful Personalized Dosing of Quinamed at,ASCO 4Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 2Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 3Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 4Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 5Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 6Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 7
Intradyn TearAway
KELLER-TIMMERMANS Introducer Set
CHECK-FLO Performer Introducers CHILDRENS HOSPITAL BOSTON Modification
FLEXOR CHECK-FLO Introducer Sets for Radial Artery Access with AQ Hydrophylic Coating
Medicine Products: